CTNNB1 and neoplasm: By longitudinal genomic analysis of liquid biopsies and tumor re-biopsies, Blakely et al. also identified EGFRM+ NSCLC patients with activating CTNNB1 co-mutations already present in early tumor stages and subsequently persisting during progression to metastatic disease, which implied that these mutations were clonal and may play a co-pathogenetic role in EGFRM+ NSCLC [12].